Text size Jason Alden / Bloomberg Data on the Covid-19 vaccine in development by AstraZeneca and the University of Oxford published in The Lancet on Monday looked positive, but the stock fell after rising last week due to high expectations for the data. Shares of the US deposit receipt for …
Read More »
Text size Maddie Meyer / Getty Images Moderna’s shares have risen 239% so far this year, and the biotech company, which has no approved medications, has a market capitalization of more than $ 24 billion. But in a note sent out Monday morning, Jefferies analyst Michael Yee writes that the …
Read More »
Text size Dirk Waem / Getty Images NASH was once the next big thing for big drug companies; a newly defined disorder that requires chronic treatment that affects millions of people in developed countries. Dozens of companies are developing drugs for the disease, which can cause life-threatening conditions like decompensated …
Read More »